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Abstract
To increase the effectiveness of cancer treatment, more effective anti-cancer drugs, as well as the new improved strate-
gies of cancer treatment, are urgently needed. Our previous results have shown that various diazenes are cytotoxic to dif-
ferent tumor cells and can even revert the resistance to cisplatin and vincristine. We also demonstrated that unsymmetri-
cal diazenedicarboxamides 1 and 2 exhibited promising cytotoxicity. The aim of the present study was to synthesize
new diazenedicarboxamides with acceptable solubility and good cytotoxicity. Here we report the synthesis and biologi-
cal evaluation of new N,N’-disubstituted diazenedicarboxamides. We found that a modification of either 1 or 2 led to the
more active compounds. The most effective among them was diazenedicarboxamide 11, which can be considered as a
new potential anticancer agent for the tumors of different origin, as well as for the drug resistant tumors.
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1. Introduction
Cancer is currently the leading cause of death in
many high-developed countries and will probably become
a major cause of mortality worldwide. One of the most
widely applied modality for cancer treatment is chemot-
herapy. However, the major obstacle for the successful
treatment of cancer patients with standard chemotherapy
is drug resistance. It is based on the alterations that are in-
duced in the cells during normal malignant transition pro-
cess,1 or those alterations that are developed during the
treatment of patients with anti-cancer drugs.2 To increase
the effectiveness of cancer treatment, new, target oriented
drugs have been developed. These, so called “smart
drugs”, are designed to act selectively against tumor cells
by targeting only specific bio-molecules present. Howe-
ver, in spite of the initial enthusiasm, these drugs did not
adequately increase the success of cancer treatment.3–5
Therefore, in order to increase the effectiveness of cancer
treatment, more effective anti-cancer drugs, as well as the
new improved strategies of cancer treatment are urgently
required.
During the last ten years, we have synthesized and
screened the cytotoxic activity of a number of compounds
from diazene family. We have shown that these com-
pounds have antiproliferative activity against different tu-
mor cell lines.6 If diazenecarboxamides were administe-
red in combination with cisplatin, one of the most com-
monly used anti-cancer drug for the treatment of various
solid tumors,7 synergistic effect was detected on several
tumor cells from different origins, as well as the reversion
of cisplatin and vincristine resistance.6a,6c,6d,6h Moreover, it
was shown that antiproliferative activity of selected diaze-
necarboxamides against tumor cells was significantly hig-
her in comparison to the normal cells.6i
Regarding the molecular mechanisms of their biolo-
gical activity we found that diazenecarboxamides can sig-
nificantly reduce the intracellular level of glutathione
(GSH).6a,6c–6e Under quasi-physiological conditions (0.15
M aqueous solution of KCl, pH 7.4, presence of air, con-
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centration of a thiol 10 mmol L–1, an equimolar amount of
a diazene, 30 °C), diazenecarboxamides can transform
different thioles to the corresponding disulphides. The sa-
me activity of diazenecarboxamides against the most im-
portant intracellular thiol, glutathione (GSH), was later
identified to take place in the living cells.6d Glutathione is
the major antioxidant in the cells.8 In addition, it interacts
with several different cytotoxic compounds, reducing
their bioavailability and thus their cytotoxicity.8b It has
been recently recognized that GSH is responsible for cel-
lular redox state maintaining,9a,9b a process that is essen-
tial for a number of physiological processes in the leaving
cell including cell proliferation, DNA synthesis, sensiti-
vity to cytotoxic compounds, cell death etc.8b,9b,9c Regar-
ding the type of the cell death that can be triggered by dia-
zenecarboxamides, both apoptosis like,6g and necrosis
type of the cell death were observed.6h
Although diazenecarboxamides that have been prepa-
red and tested so far possess several desired characteristics,
their main disadvantage in view of potential clinical appli-
cation is the low solubility in aqueous media. Therefore the
aim of the present study was to synthesize new diazenedi-
carboxamides, structurally similar to the compounds 1 and
2, with improved solubility and a good cytotoxicity.
2. Chemistry
Unsymmetrical diazenedicarboxamides, also shortly
referred to as diazenes, employed in this study were obtain-
ed starting from the commercially available isocyanates
A. The only exception was 4-butylphenyl isocyanate,
which we prepared in-situ from 4-butylaniline and trip-
hosgene following the procedure described for the forma-
tion of isocyanates from primary amines.10 The reaction
of a selected isocyanate A with ethyl carbazate B gave the
corresponding 1,4-disubstituted semicarbazide (com-
pounds C1–C6). This was oxidized with N-bromosuccin-
imide (NBS) leading to the ethyl diazenecarboxylate
(compounds D1–D6) and in the final stage, through a nuc-
leophilic substitution of the ethoxy group in D with the
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appropriate picolylamine, transformed into the diazenedi-
carboxamide shown in Scheme 1 (compounds 3–19). 
The entire sequence was performed under mild reac-
tion conditions and led to high yields of the desired com-
pounds 3–19 (Chart 1). The final products are crystalline
compounds that are stable at room temperature in a solid
state for months. 
3. Results and Discussion
Our recent study revealed that diazenedicarboxami-
des 1 and 2 exhibited promising cytotoxicity.11 Interest-
ingly, however, compound 2 containing 3-picolyl moiety
Scheme 1. Synthetic approach to diazenedicarboxamides 3–19. 
Chart 1. The structures of the diazenedicarboxamides 1–19.
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at the amide nitrogen atom turned out to be more active
than the analogue 1 having 2-picolyl group at the same
position. This prompted us to check cytotoxicity of
unsymmetrical diazenedicarboxamides possessing 2-pi-
colyl, 3-picolyl or 4-picolyl group at one of the amide ni-
trogen atom and 4-substituted phenyl group at the other.
The screening of their cytotoxic activity was carried out
on human cervical carcinoma (HeLa) cells (Table 1). 
butylphenyl functionalized analogous (7, 13 and 18). Un-
fortunately, the diazenes 6, 12 and 17 precipitated prompt-
ly after their addition to the growth medium and thus the
cytotoxicity could not be determined accurately. For other
diazenes having 4-alkylphenyl group at the amide functio-
nality, the bulkiness rather than the length of the alkyl frag-
ment seems to have an effect on their activity. Namely, ste-
ric hindrance of the alkyl moiety increases as follows: iso-
propyl, sec-butyl, tert-butyl. In the same sequence cytoto-
xicity of the compounds decreases; compare the results for
5, 7 and 8 in 2-picolyl series, 11 and 13 in 3-picolyl and the
results for 16, 18 and 19 in 4-picolyl series. Comparing a
biological activity and the nature of the substituent on the
benzene ring one can conclude that a nonpolar alkyl group
at the para position is more appropriate than the chloro or
methoxy substituent at the same position. 
The above figures clearly demonstrate that 3-picolyl
diazenedicarboxamides are more active against HeLa cell
lines than analogous 2-picolyl and 4-picolyl derivatives.
This stimulated us to screen the biological activity of three
mostly cytotoxic 3-picolyl representatives, namely 10, 11
and 13 against several other tumor cell lines, including
drug-resistant subline. The results outlined in Table 2 in-
dicate that all three diazenedicarboxamides inhibited the
growth of all examined tumor cell lines. This antiprolife-
rative activity was strongly expressed for the compounds
11 and 13, and significantly less for the diazene 10. Alt-
hough the diazene 11 exhibited some tumor cell-type spe-
cific cytotoxicity, being mostly toxic against HeLa cells,
similar cytotoxic to laryngeal carcinoma HEp-2 and colo-
rectal carcinoma HCT-116 cells, and the least active
against lung adenocarcinoma H460 cells, the difference in
its biological vary less than 1.5 fold (as determined by
IC50). Contrary, the diazene 13 was similarly cytotoxic
against all tumor cells lines. It is important to point out
that both, 11 and 13, were similarly active against parental
HEp-2 cells and their drug-resistant subline, what is high-
ly important keeping in mind that the drug-resistant cells
are the major cause for an unsuccessful chemotherapy
with the standard anti-cancer drugs. The cytotoxic activity
of the least active of the three compounds, the diazene 10,
depends on the origin of the tumor cells: it was mostly
cytotoxic against cervical carcinoma HeLa cells, followed
by laryngeal carcinoma HEp-2 cells. Unfortunately, car-
boplatin resistant cells 7T were more than two times more
Table 1. Cytotoxic activity of diazenedicarboxamides against hu-





3 141.7 ± 0.1
4 88.9 ± 33.3
5 28.2 ± 4.1
6 23.9 ± 3.1b
7 56.6 ± 14.5
8 61.3 ± 24.3
9 46.1 ± 1.0
10 34.5 ± 4.1
11 18.9 ± 4.0
12 12.4 ± 6.0b
13 25.4 ± 5.6 
14 92.5 ± 15.9
15 233.9 ± 69.1
16 25.8 ± 5.7
17 14.1 ± 4.3b
18 57.4 ± 2.6
19 257.0 ± 2.3
a IC50 is the concentration of the diazene inducing 50% cell growth
inhibition after 72 h incubation. 
b Diazenedicarboxamide precipitated promptly after the addition to
the growth medium and thus the cytotoxicity cannot be measured
accurately.
As evident from Table 1, out of the diazenes having
the same aryl group in their structures, the compounds
bearing 3-picolyl moiety are more cytotoxic than those
with either 2-picolyl or 4-picolyl substituent. The compa-
rison should be made among 4-chlorophenyl (3, 9 and
14), 4-methoxyphenyl (4, 10 and 15), 4-isopropylphenyl
(5, 11 and 16), 4-butylphenyl (6, 12 and 17), and 4-sec-
Table 2. Cytotoxic activity of the diazenedicarboxamides 10, 11 and 13 against different tumor cell lines ex-
pressed as IC50 value (μM).
Compound HeLa HEp2 7T H460 HCT-116
10 34.5 ± 4.9 40.1 ± 2.3 88.8 ± 8.4 148.6 ± 4.6 164.0 ± 11.3
11 18.9 ± 4.0 22.5 ± 3.8 26.2 ± 2.4 27.6 ± 7.7 21.1 ± 2.1
13 25.4 ± 5.6 25.3 ± 4.3 23.3 ± 3.8 26.5 ± 3.8 21.6 ± 2.6
IC50 is the concentration of test compound inducing 50% cell growth inhibition after 72 h incubation; HeLa =
human cervical carcinoma cells; HEp-2 = laryngeal carcinoma cells; 7T = drug-resistant HEp-2 subline; H460
= lung adenocarcinoma H460 cells; HCT-116 = colorectal carcinoma cells.
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resistant to 10 as their parental HEp-2 cells. Furthermore,
the lung adenocarcinoma H460 cells were more than four
times more resistant to 10 comparing to the sensitivity of
HeLa cells. Finally, the colorectal carcinoma HCT-116
cells were found to be the most resistant among the exa-
mined cell lines.
While several diazenecarboxamides can reduce intra-
cellular glutathione level,6a,6c–6e thus reducing the survival
of treated cells, we investigated whether glutathione is in-
volved in the cell response to 10. In order to get this answer
we pretreated the cells with buthionine sulfoximine (BSO),
the well-known inhibitor of glutathione synthesis.12 The re-
sults presented in Table 3 clearly show that the depletion of
glutathione did not alter the survival of the cells treated
with 10. Such a pretreatment slightly increases the cytoto-
xicity of 11 and 13 indicating that glutathione is also not in-
volved in the cell response to these diazenes.
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Table 3. Survival of HeLa cells following the treatment with 10, 11
and 13, with or without a pretreatment with BSOa expressed as IC50
value (μM).
Diazene Control + BSO
10 36.5 ± 2.3 35.6 ± 1.9
11 17.7 ± 2.9 14.3 ± 4.8
13 23.0 ± 2.7 18.6 ± 0.2
a BSO: buthionine sulfoximine.
Figure 1. The diazenes 10, 11 and 13 induce necrosis in HeLa cells. a) Control cells. Cells, stained with tripan blu dye 1 hour after cell treatment
with: b) 34 μM of 10; c) 100 μM of 11; d) 80 μM of 13. Phase contrast images of cells grown in culture.
a) b)
d)c)
Finally, as diazenecarboxamides can induce diffe-
rent types of cell death,6g,6h we examined which type is
triggered by the compounds 10, 11 and 13. As evident
from Figure 1 all three selected diazenecarboxamides in-
duced very fast necrosis that could be observed within 1
hour after cell treatment.
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4. Conclusions
We have shown that all new diazenedicarboxamides
are highly cytotoxic against human carcinoma cells.
Among the analogues, having the same aryl group, the
compounds bearing 3-picolyl functionality are more cyto-
toxic than those possessing either 2-picolyl or 4-picolyl
substituent. For the diazenedicarboxamides with 4-alkyl-
phenyl group at one of the amide nitrogen atom it turned
out that an increased bulkiness of the alkyl chain resulted
in the decreased cytotoxicity.
From the series of the examined compounds, the
diazene 11 was found to be the most cytotoxic that indu-
ced necrosis in the treated cells. Our results concerning
the diazenedicarboxamide 11 indicate as follows: (a) it is
mostly cytotoxic against human cervical carcinoma HeLa
cells; (b) it is biologically active against a number of tu-
mor cell lines; (c) it exhibits similar cytotoxicity against
parental HeEp-2 cells and their drug-resistant subline.
Therefore, the diazene 11 could be considered as a new
potential anticancer agent for the tumors of different ori-




Starting materials for the synthesis of the examined
compounds were used as obtained from the commercial
sources (Aldrich, Fluka, Alfa Aesar, Maybridge Chemical
Company Ltd). Melting points were determined on a Kof-
ler micro hot stage and are uncorrected. NMR spectra we-
re recorded at 29 °C with a Bruker Avance DPX 300 spec-
trometer (1H NMR spectra at 300 MHz; 13C NMR spectra
at 75 MHz) and with a Bruker Avance III spectrometer
(1H NMR spectra at 500 MHz; 13C NMR spectra at 126
MHz). Proton spectra are referenced to TMS as an inter-
nal standard; the carbon shifts are given against the central
line of the solvent signal (DMSO-d6 at δ = 39.5 ppm;
CDCl3 at δ = 77.1 ppm). IR spectra were obtained with a
Perkin–Elmer Spectrum 100, equipped with a Specac
Golden Gate Diamond ATR as a solid sample support.
High-resolution mass spectra with atmospheric pressure
electrospray ionization (HRMS ESI) were recorded with
an Agilent 6224 Accurate Mass TOF LC/MS spectro-
meter. FAB spectra were obtained with VG-Analytical
Autospec EQ instrument. Elemental analyses (C, H, N)
were performed with Perkin Elmer 2400 Series II
CHNS/O Analyzer. TLC was carried out on Fluka silica-
gel TLC-cards.
Semicarbazides C113a and C213b were previously
described in the literature but their syntheses and charac-
terization details were not provided. For this reason they
were prepared following our general synthesis to obtain
semicarbazides C and all the missing data are reported.
Diazenedicarboxamides 1,11 211 and 17,14 already
described in the literature, as well as the new ones were
prepared following a general procedure given underneath. 
All tested compounds possessed a purity of ≥95% as
verified by 1H NMR and 13C NMR spectroscopy and with
elemental microanalysis. All results of C, H, N analyses
were within ±0.35% of the calculated values. 
5. 1. 1. General Procedure for the Synthesis 
of Semicarbazides C
A modified procedure we described earlier14 was
employed for the synthesis of semicarbazides. A solution
of the appropriate 4-substituted phenyl isocyanate A (5
mmol) in acetonitrile (3 mL) was added dropwise to the
solution of ethyl carbazate B (0.520 g, 5 mmol) in aceto-
nitrile (3 mL). The reaction mixture was stirred for 20 min
at 0 °C and then for 18 h at room temperature, evaporated
to dryness and treated with diethyl ether (7–10 mL). The
solid material was filtered off and washed with hexane to
afford the desired C. Crude product was crystallized from
acetonitrile. 
Ethyl 2-((4-chlorophenyl)carbamoyl)hydrazinecar-
boxylate (C1; R1 = 4-Cl)
Reaction time: 0.5 h, colorless solid, yield: 0.938 g (73%),
mp 200–201 °C (MeCN); mp13a 193–195 °C; IR: υ 3281,
2981, 1737, 1685, 1636, 1590, 1554, 1524, 1493, 1403,
1369, 1308, 1254, 1232, 1208, 1088 cm–1; 1H NMR (500
MHz, DMSO-d6): δ (ppm) 1.20 (t, J = 6.8 Hz, 3H), 4.06
(q, J = 6.8 Hz, 2H), 7.28–7.31 (m, 2H), 7.45–7.57 (m,
2H), 8.10 (s, 1H), 8.85–8.99 (m, 2H); 13C NMR (126
MHz, DMSO-d6): δ (ppm) 14.4, 60.4, 119.9, 125.2, 128.3,
138.6, 155.4, 156.8; HRMS (ESI+) Calcd for C10H13Cl-
N3O3 [M + H]+: 258.0640; Found 258.0642. Anal. Calcd
for C10H12ClN3O3: C, 46.61; H, 4.69; N, 16.31. Found: C,
46.60; H, 4.51; N, 16.52.
Ethyl 2-((4-methoxyphenyl)carbamoyl)hydrazinecar-
boxylate (C2; R1 = 4-MeO)
Reaction time: 0.5 h, colorless solid, yield: 0.772 g (61%),
mp 164.5–166.5 °C (MeCN); mp13b 170.5–171.5 °C; IR:
υ 3320, 3279, 1739, 1681, 1637, 1612, 1598, 1559, 1515,
1455, 1297,3 1236, 1206, 1189, 1032 cm–1; 1H NMR (500
MHz, DMSO-d6): δ (ppm) 1.19 (t, J = 6.8 Hz, 3H), 3.70
(s, 3H), 4.05 (q, J = 6.8 Hz, 2H), 6.80–6.87 (m, 2H),
7.30–7.40 (m, 2H), 7.90 (s, 1H), 8.54 (s, 1H), 8.88 (s,
1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 14.4, 55.0,
60.4, 113.6, 120.1, 132.6, 154.3, 155.7, 156.9; HRMS
(ESI+) Calcd for C11H16N3O4 [M + H]+: 254.1135; Found
254.1133. Anal. Calcd for C11H15N3O4: C, 52.17; H, 5.97;
N, 16.59. Found: C, 52.25; H, 5.96; N, 16.66.
Ethyl 2-((4-isopropylphenyl)carbamoyl)hydrazinecar-
boxylate (C3; R1 = 4-i-Pr)
Reaction time: 18 h, colorless solid, yield: 0.835 g (63%),
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mp 138.5–139.5 °C (MeCN); IR: υ 3344, 3204, 3114,
2952, 2866, 1740, 1691, 1594, 1534, 1514 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 1.09–1.24 (m, 9H), 2.80
(sep, J = 7.0 Hz, 1H), 4.05 (q, J = 7.0 Hz, 2H), 7.07–7.15
(m, 2H), 7.29–7.40 (m, 2H), 7.92 (s, 1H), 8.60 (s, 1H),
8.89 (s, 1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm)
14.5, 24.0, 32.8, 60.5, 118.6, 126.3, 137.4, 141.8, 155.6,
157.0; HRMS (ESI+) Calcd for C13H20N3O3 [M + H]+:
266.1499; Found 266.1495. Anal. Calcd for C13H19N3O3:
C, 58.85; H, 7.22; N, 15.84. Found: C, 58.66; H, 7.36; N,
15.84.
Ethyl 2-((4-(sec-butyl)phenyl)carbamoyl)hydrazine-
carboxylate (C5; R1 = 4-sec-Bu)
Reaction time: 0.5 h, colorless solid, yield: 0.962 g (69%),
mp 97.5–99.5 °C (MeCN); IR: υ 3262, 2959, 2926, 2872,
1730, 1678, 1605, 1539, 1514, 1462 cm–1; 1H NMR (500
MHz, DMSO-d6): δ (ppm) 0.75 (t, J = 7.5 Hz, 3H),
1.09–1.24 (m, 6H), 1.45–1.57 (m, 2H), 4.05 (q, J = 7.5
Hz, 2H), 7.06 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.5 Hz,
2H), 7.93 (s, 1H), 8.61 (s, 1H), 8.90 (s, 1H), (1 signal hid-
den beneath DMSO – proved by HSQC spectrum); 13C
NMR (126 MHz, DMSO-d6): δ (ppm) 12.1, 14.6, 21.9,
30.7, 40.3, 60.5, 118.6, 126.9, 137.4, 140.5, 155.7, 157.0;
HRMS (ESI+) Calcd for C14H22N3O3 [M + H]+: 280.1656;
Found 280.1649. Anal. Calcd for C14H21N3O3: C, 60.20;
H, 7.58; N, 15.04. Found: C, 59.92; H, 7.88; N, 15.06.
Ethyl 2-((4-(tert-butyl)phenyl)carbamoyl)hydrazine-
carboxylate (C6; R1 = 4-t-Bu)
Reaction time: 1 h, colorless solid, yield: 0.843 g (60%),
mp 173.0–175.0 °C (MeCN); IR: υ 3346, 3206, 3116,
2948, 2903, 2868, 1742, 1689, 1593, 1530 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 1.19 (t, J = 7.0 Hz, 3H),
1.24 (s, 9H), 4.05 (q, J = 7.0 Hz, 2H), 7.22–7.28 (m, 2H),
7.30–7.40 (m, 2H), 7.92 (s, 1H), 8.62 (s, 1H), 8.90 (s,
1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 14.6, 31.2,
33.8, 60.5, 118.3, 125.2, 137.0, 144.0, 155.6, 157.0;
HRMS (ESI+) Calcd for C14H22N3O3 [M + H]+: 280.1656;
Found 280.1648. Anal. Calcd for C14H21N3O3: C, 60.20;
H, 7.58; N, 15.04. Found: C, 59.96; H, 7.73; N, 14.99.
Synthesis of Ethyl 2-((4-Butylphenyl)carbamoyl)hy-
drazinecarboxylate (C4; R1 = 4-Bu)
A solution of 4-butylaniline (3.014 g, 20.2 mmol) in dry
dichloromethane (60 mL, distilled over P2O5) was added
dropwise to the solution of triphosgene (2.404 g, 8 mmol)
in dry dichloromethane (100 mL) at room temperature.
The reaction mixture was stirred at room temperature for
30 min. Then, a solution of triethylamine (5.86 mL, 42
mmol) in dry dichloromethane (60 mL) was added drop-
wise. After 30 min ethyl carbazate was added (2.120 g,
20.2 mmol). The reaction mixture was stirred at room
temperature for additional 20 min and evaporated under
reduced pressure. Then water (100 mL) was added and the
aqueous phase was washed with ethyl acetate (3×200 m-
L). Combined organic phases were dried over anhydrous
Na2SO4, filtered and evaporated under reduced pressure to
dryness, leading to C4. Crude product was crystallized
from petroleum ether/ethyl acetate.
Colorless solid, yield: 3.45 g (61%), mp
155.0–157.5 °C (petroleum ether/ethyl acetate); IR: υ
3274, 2959, 2929, 2858, 1744, 1681, 1642, 1597, 1551,
1516 cm–1; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 0.88
(t, J = 7.5 Hz, 3H), 1.19 (t, J = 7.0 Hz, 3H), 1.24–1.33 (m,
2H), 1.46–1.55 (m, 2H), 2.45–2.52 (m, 2H), 4.05 (q, J =
7.0 Hz, 2H), 7.02–7.09 (m, 2H), 7.30–7.40 (m, 2H), 7.93
(s, 1H), 8.61 (s, 1H), 8.90 (s, 1H); 13C NMR (126 MHz,
DMSO-d6) δ (ppm) 13.8, 14.5, 21.7, 33.3, 34.1, 60.5,
118.6, 128.3, 135.6, 137.2, 155.6, 157.0; HRMS (ESI+)
Calcd for C14H22N3O3 [M + H]+: 280.1656; Found
280.1656. Anal. Calcd for C14H21N3O3: C, 60.20; H, 7.58;
N, 15.04. Found: C, 60.27; H, 7.71; N, 14.92.
5. 1. 2. General Procedure for the Synthesis 
of Diazenecarboxylates D
A modified procedure we described earlier15 was emplo-
yed for the synthesis of diazenecarboxylates. Pyridine
(0.808 mL, 10 mmol) was added to the solution of the ap-
propriate semicarbazide C (5 mmol) in dichloromethane
(18 mL). Then, NBS (0.907 g, 5.1 mmol) was added and
the reaction mixture was stirred at room temperature for 1
h, washed with aqueous HCl (1:1, 18 mL), sodium thio-
sulfate (2.5%, 18 mL), saturated aqueous solution of Na-
HCO3 (18 mL), brine (18 mL). Organic phase was dried
over anhydrous Na2SO4, filtered and evaporated under re-
duced pressure to give product D. Solid products were
crystallized from dichloromethane.
Ethyl 2-((4-chlorophenyl)carbamoyl)diazenecarboxy-
late (D1; R1 = 4-Cl) 
Orange solid, yield: 1.150 g (90%), mp 88.4–89.8 °C
(CH2Cl2); IR: υ 3313, 1763, 1745, 1714, 1602, 1565,
1525, 1490, 1461, 1399, 1366, 1297, 1225, 1120, 1087,
1033 cm–1; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 1.38
(t, J = 7.1 Hz, 3H), 4.52 (q, J = 7.1 Hz, 2H), 7.47–7.53
(m, 2H), 7.73–7.80 (m, 2H), 11.72 (s, 1H); 13C NMR (126
MHz, DMSO-d6): δ (ppm) 13.8, 65.4, 115.0, 121.2, 129.0,
136.1, 156.8, 161.2; HRMS (ESI+) Calcd for C10H11Cl-
N3O3 [M + H]+: 256.0483; Found 256.0482. Anal. Calcd
for C10H10ClN3O3: C, 46.98; H, 3.94; N, 16.44. Found: C,
47.00; H, 3.74; N, 16.32.
Ethyl 2-((4-methoxyphenyl)carbamoyl)diazenecar-
boxylate (D2; R1 = 4-MeO)
Red solid, yield: 1.217 g (97%), mp 72.5–73.3 °C
(CH2Cl2); IR: υ 3249, 1759, 1739, 1715, 1601, 1557,
1509, 1468, 1418, 1371, 1302, 1257, 1231, 1200, 1173,
1116, 1027, 1016 cm–1; 1H NMR (500 MHz, DMSO-d6):
δ (ppm) 1.37 (t, J = 7.1 Hz, 3H), 3.76 (s, 3H), 4.52 (q, J =
7.1 Hz, 2H), 6.95–7.03 (m, 2H), 7.64–7.71 (m, 2H), 11.49
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(s, 1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 13.9,
55.2, 65.3, 114.2, 121.1, 130.2, 156.3, 156.6, 161.5;
HRMS (ESI+) Calcd for C11H14N3O4 [M + H]+: 252.0979;
Found 252.0975. Anal. Calcd for C11H13N3O4: C, 52.39;
H, 5.22; N, 16.73. Found: C, 52.69; H, 5.82; N, 16.65.
Ethyl 2-((4-isopropylphenyl)carbamoyl)diazenecar-
boxylate (D3; R1 = 4-i-Pr)
Orange solid, yield: 1.24 g (94%), mp 65.5–67.0 °C
(CH2Cl2); IR: υ 3274, 2999, 2959, 2875, 1778, 1718,
1597, 1558, 1526, 1470 cm–1; 1H NMR (500 MHz, DM-
SO-d6): δ (ppm) 1.19 (d, J = 6.5 Hz, 6H) 1.37 (t, J = 7.0
Hz, 3H), 2.87 (sep, J = 6.5 Hz, 1H) 4.51 (q, J = 7.0 Hz,
2H), 7.24–7.33 (m, 2H), 7.61–7.69 (m, 2H), 11.49 (s, 1H);
13C NMR (126 MHz, DMSO-d6): δ (ppm) 13.9, 23.8,
33.0, 65.4, 119.7, 126.9, 135.0, 145.4, 156.9, 161.5;
HRMS (ESI+) Calcd for C13H18N3O3 [M + H]+: 264.1343;
Found 264.1340. Anal. Calcd for C13H17N3O3: C, 59.30;
H, 6.51; N, 15.96. Found: C, 59.09; H, 6.42; N, 15.67.
Ethyl 2-((4-butylphenyl)carbamoyl)diazenecarboxyla-
te (D4; R1 = 4-Bu)
Red oil, yield: 1.370 g (99%); IR: υ 3275, 2957, 2929,
2858, 1728, 1599, 1514, 1466, 1414, 1233 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 0.90 (t, J = 7.5 Hz, 3H),
1.25–1.41 (m, 5H), 1.46–1.60 (m, 2H), 2.53–2.61 (m,
2H), 4.52 (q, J = 7.5 Hz, 2H), 7.21–7.27 (m, 2H),
7.60–7.63 (m, 2H), 11.50 (s, 1H); 13C NMR (126 MHz,
DMSO-d6) δ (ppm) 13.7, 13.9, 21.7, 33.1, 34.2, 65.4,
119.6, 128.9, 134.9, 139.3, 156.8, 161.4; HRMS (ESI+)
Calcd for C14H20N3O3 [M + H]+: 278.1499; Found
278.1498.
Ethyl 2-((4-(sec-butyl)phenyl)carbamoyl)diazenecar-
boxylate (D5; R1 = 4-sec-Bu)
Red oil, yield: 1.355 g (98%); IR: υ 3284, 2960, 2929,
2873, 1769, 1721, 1597, 1557, 1517, 1454 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 0.76 (t, J = 7.5 Hz, 3H),
1.18 (d, J = 7.0 Hz, 3H), 1.37 (t, J = 7.0 Hz, 3H),
1.48–1.60 (m, 2H), 2.55–2.62 (m, 1H), 4.51 (q, J = 7.5
Hz, 2H), 7.20–7.28 (m, 2H), 7.61–7.69 (m, 2H), 11.49 (s,
1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 12.0, 13.9,
21.7, 30.5, 40.4, 65.4, 119.7, 127.5, 135.0, 144.1, 156.9,
161.5; HRMS (ESI+) Calcd for C14H20N3O3 [M + H]+:
278.1499; Found 278.1491.
Ethyl 2-((4-(tert-butyl)phenyl)carbamoyl)diazenecar-
boxylate (D6; R1 = 4-t-Bu) 
Orange oil, yield: 1.342 g (97%); IR: υ 3274, 2962, 2869,
1766, 1726, 1598, 1518, 1474, 1408, 1365 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 1.28 (s, 9H), 1.37 (t, J =
7.0 Hz, 3H), 4.51 (q, J = 7.0 Hz, 2H), 7.40–7.47 (m, 2H),
7.61–7.69 (m, 2H), 11.49 (s, 1H); 13C NMR (126 MHz,
DMSO-d6): δ (ppm) 13.9, 31.1, 34.2, 65.4, 119.5, 125.8,
134.7, 147.6, 156.9, 161.5; HRMS (ESI+) Calcd for
C14H23N4O3 [M + NH4]+: 295.1765; Found 295.1761.
5. 1. 3. General Procedure for the Synthesis 
Diazenedicarboxamides
A modified procedure we described earlier16 was
employed for the synthesis of diazenedicarboxamides. A
solution of the appropriate picolyl amine (0.108 g, 1
mmol) in acetonitrile (2.5 mL) was added to the solution
of the selected diazenecarboxylate D (1 mmol) in acetoni-
trile (2.5 mL). The reaction mixture was stirred for 1 h at
0 °C, solid material was filtered off and washed with ace-
tonitrile at 0 °C to give the final product. The synthesis of
5–8 was carried out in methanol. The reaction mixture
was stirred at –15 °C for 1 h, then at rt for 20 h, evapora-
ted to dryness and the residue was purified by column
chromatography using ethyl acetate or ethyl acetate/petro-
leum ether (1:1) as a solvent to obtain the desired diazene-




Orange solid, yield: 0.216 g (68%), mp 149.5–151.5 °C
(MeOH); IR: υ 3315, 3237, 2988, 1741, 1707, 1599,
1589, 1568, 1516, 1490, 1434, 1424, 1402, 1359, 1305,
1258, 1245, 1216, 1147, 1087 cm–1; 1H NMR (500 MHz,
DMSO-d6): δ (ppm) 4.59 (d, J = 6.1 Hz, 2H), 7.30–7.35
(m, 1H), 7.38–7.43 (m, 1H), 7.47–7.52 (m, 2H),
7.74–7.79 (m, 2H), 7.80–7.85 (m, 1H), 8.53–8.57 (m,
1H), 9.60 (t, J = 6.1 Hz, 1H), 11.53 (s, 1H); 13C NMR
(126 MHz, DMSO-d6): δ (ppm) 45.3, 121.1, 121.3, 122.6,
128.7, 129.1, 136.4, 136.9, 149.1, 157.1, 158.1, 161.9;
HRMS (ESI+) Calcd for C14H13ClN5O2 [M + H]+:
318.0752; Found 318.0752. Anal. Calcd for C14H12Cl-




Red solid, yield: 0.152 g (49%), mp 139.5–141.0 °C (Me-
OH); IR: υ 3234, 2969, 1735, 1709, 1600, 1589, 1570,
1530, 1507, 1468, 1435, 1412, 1354, 1303, 1263, 1230,
1179, 1078, 1027 cm–1; 1H NMR (500 MHz, DMSO-d6):
δ (ppm) 3.76 (s, 3H), 4.58 (d, J = 6.1 Hz, 2H), 6.95–7.02
(m, 2H), 7.29–7.35 (m, 1H), 7.38–7.42 (m, 1H),
7.63–7.69 (m, 2H), 7.79–7.85 (m, 1H), 8.52–8.57 (m,
1H), 9.54 (t, J = 6.0 Hz, 1H), 11.28 (s, 1H); 13C NMR
(126 MHz, DMSO-d6): δ (ppm) 45.3, 55.3, 114.3, 121.0,
121.3, 122.5, 130.5, 136.9, 149.1, 156.4, 157.1, 157.8,
162.2; HRMS (ESI+) Calcd for C15H16N5O3 [M + H]+:
314.1248; Found 314.1246. Anal. Calcd for C15H15N5O3:




Orange solid, yield: 0.238 g (73%), mp 119.0–120.5 °C
(ethyl acetate); IR: υ 3227, 3048, 2953, 1741, 1708, 1591,
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1571, 1516, 1473, 1435 cm–1; 1H NMR (500 MHz, DM-
SO-d6): δ (ppm) 1.20 (d, J = 7.0 Hz, 6H), 2.88 (sep, J =
7.0 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 7.25–7.35 (m, 3H),
7.38–7.43 (m, 1H), 7.62–7.69 (m, 2H), 7.78–7.86 (m,
1H), 8.53–8.58 (m, 1H), 9.56 (t, J = 6.0 Hz, 1H), 11.29 (s,
1H); 13C NMR (126 MHz, DMSO-d6) δ (ppm) 23.9, 32.9,
45.3, 119.6, 121.3, 122.5, 126.9, 135.2, 136.9, 145.0,
149.0, 157.1, 158.1, 162.1; HRMS (ESI+) Calcd for
C17H20N5O2 [M + H]+: 326.1612; Found 326.1609. Anal.
Calcd for C17H19N5O2: C, 62.75; H, 5.89; N, 21.52.
Found: C, 62.76; H, 5.75; N, 21.45.
N1-(4-Butylphenyl)-N2-(pyridin-2-ylmethyl)diazene-
1,2-dicarboxamide (6)
Yellow solid, yield: 0.239 g (70%), mp 122.5–124.0 °C
(petroleum ether/ethyl acetate); IR: υ 3262, 2954, 2928,
2854, 1752, 1709, 1688, 1594, 1531, 1514 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 0.90 (t, J = 7.5 Hz, 3H),
1.25–1.35 (m, 2H), 1.50–1.60 (m, 2H), 2.57 (t, J = 7.5 Hz,
2H), 4.59 (d, J = 6.0 Hz, 2H), 7.20–7.26 (m, 2H),
7.30–7.35 (m, 1H), 7.38–7.43 (m, 2H), 7.61–7.69 (m,
1H), 7.79–7.85 (m, 1H), 8.53–8.58 (m, 1H), 9.56 (t, J =
6.0 Hz, 1H), 11.29 (s, 1H); 13C NMR (126 MHz, DMSO-
d6) δ (ppm) 13.7, 21.7, 33.1, 34.2, 45.3, 119.5, 121.3,
122.5, 128.8, 135.1, 136.9, 139.0, 149.1, 157.1, 158.0,
162.1; HRMS (ESI+) Calcd for C18H22N5O2 [M + H]+:
340.1766; Found 340.1766. Anal. Calcd for C18H21N5O2:




Orange solid, yield: 0.195 g (57%), mp 93.5–94.5 °C (pe-
troleum ether/ethyl acetate); IR: υ 3230, 2959, 2926,
2872, 1709, 1593, 1571, 1516, 1473, 1435 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 0.77 (t, J = 7.5 Hz, 3H),
1.18 (d, J = 7.0 Hz 3H), 1.48–1.60 (m, 2H), 2.55–2.62 (m,
J = 6.0 Hz, 1H), 4.58 (d, J = 6.0 Hz, 2H), 7.21–7.27 (m,
2H), 7.30–7.34 (m, 1H), 7.38–7.42 (m, 1H), 7.62–7.67
(m, 2H), 7.79–7.85 (m, 1H), 8.53–8.57 (m, 1H), 9.56 (t, J
= 6.0 Hz, 1H), 11.29 (s, 1H); 13C NMR (126 MHz, DM-
SO-d6) δ (ppm) 12.1, 21.7, 30.5, 40.0, 45.3, 119.6, 121.3,
122.6, 127.5, 135.2, 137.0, 143.9, 149.1, 157.1, 158.1,
162.1; HRMS (ESI+) Calcd for C18H22N5O2 [M + H]+:
340.1768; Found 340.1764. Anal. Calcd for C18H21N5O2 ×
0.33 H2O: C, 62.59; H, 6.32; N, 20.28. Found: C, 62.59;
H, 6.03; N, 20.00.
N1-(4-(tert-Butyl)phenyl)-N2-(pyridin-2-ylmethyl)dia-
zene-1,2-dicarboxamide (8)
Orange solid, yield: 0.254 g (75%), mp 105.5–108.5 °C
(petroleum ether/ethyl acetate); IR: υ 3228, 3049, 2952,
1739, 1709, 1592, 1571, 1516, 1571, 1516 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ (ppm) 1.28 (s, 9H), 4.59
(d, J = 6.0 Hz, 2H), 7.30–7.35 (m, 1H), 7.38–7.47 (m,
3H), 7.62–7.86 (m, 2H), 7.79–7.86 (m, 1H), 8.531–8.580
(m, 1H), 9.56 (t, J = 6.0 Hz, 1H) 11.29 (s, 1H); 13C NMR
(126 MHz, DMSO-d6) δ (ppm) 31.1, 34.1, 45.3, 119.3,
121.3, 122.5, 125.8, 134.9, 136.9, 147.3, 149.1, 157.1,
158.1, 162.1; HRMS (ESI+) Calcd for C18H22N5O2 [M +
H]+: 340.1768; Found 340.1763. Anal. Calcd for
C18H21N5O2: C, 63.70; H, 6.24; N, 20.64. Found: C,
63.73; H, 6.12; N, 20.47.
N1-(4-Chlorophenyl)-N2-(pyridin-3-ylmethyl)diazene-
1,2-dicarboxamide (9)
Orange solid, yield: 0.220 g (70 ), mp 168.0–169.5 °C
(MeOH); IR: υ 3332, 2951, 1732, 1712, 1609, 1596,
1541, 1512, 1489, 1439, 1426, 1400, 1345, 1308, 1250,
1234, 1189, 1089 cm–1; 1H NMR (500 MHz, DMSO-d6):
δ (ppm) 4.53 (d, J = 6.0 Hz, 2H), 7.39–7.44 (m, 1H),
7.46–7.51 (m, 2H), 7.72–7.79 (m, 3H), 8.50–8.53 (m,
1H), 8.57–8.61 (m, 1H), 9.63 (t, J = 6.0 Hz, 1H), 11.54 (s,
1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 41.2,
121.1, 123.6, 128.7, 129.1, 133.6, 135.4, 136.4, 148.6,
149.0, 158.0, 161.8; HRMS (ESI+) Calcd for C14H13Cl-
N5O2 [M + H]+: 318.0750; Found 318.0764. Anal. Calcd
for C14H12ClN5O2: C, 52.92; H, 3.81; N, 22.04. Found: C,
52.86; H, 3.84; N, 22.05.
N1-(4-Methoxyphenyl)-N2-(pyridin-3-ylmethyl)diaze-
ne-1,2-dicarboxamide (10)
Orange solid, yield: 0.189 g (60%), mp 146.5–147.5 °C
(MeOH); IR: υ 3295, 2928, 1741, 1698, 1608, 1580,
1545, 1509, 1484, 1463, 1444, 1432, 1422, 1336, 1301,
1273, 1241, 1184, 1171, 1112, 1034, 1013 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 3.75 (s, 3H), 4.51 (d, J =
6.1 Hz, 2H), 6.96–7.01 (m, 2H), 7.39–7.44 (m, 1H),
7.63–7.68 (m, 2H), 7.75–7.79 (m, 1H), 8.49–8.53 (m,
1H), 8.57–8.61 (m, 1H), 9.56 (t, J = 6.1 Hz, 1H), 11.28 (s,
1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 41.1, 55.3,
114.3, 121.0, 123.6, 130.5, 133.7, 135.4, 148.6, 149.0,
156.4, 157.7, 162.2; HRMS (ESI+) Calcd for C15H16N5O3
[M + H]+: 314.1248; Found 314.1250. Anal. Calcd for
C15H15N5O3: C, 57.50; H, 4.83; N, 22.35. Found: C,
57.44; H, 4.63; N, 22.28.
N1-(4-Isopropylphenyl)-N2-(pyridin-3-ylmethyl)diaze-
ne-1,2-dicarboxamide (11)
Yellow crystals, yield: 0.276 g (85%), mp 123–126 °C
(ethyl acetate); IR: υ 3227, 3050, 2691, 1713, 1551, 1514,
1431, 1422, 1262 cm–1; 1H NMR (500 MHz, CDCl3): δ
(ppm) 1.23 (d, J = 6.9 Hz, 6H), 2.90 (sep, J = 6.9 Hz, 1H),
4.63 (d, J = 6.2 Hz, 2H), 7.20–7.27 (m, 3H), 8.58 (d, J =
8.5 Hz, 2H), 7.67–7.70 (m, 1H), 8.19–8.24 (m, 1H),
8.48–8.51 (m, 1H), 8.59 (d, J = 1.8 Hz, 1H), 9.68 (s, 1H);
13C NMR (126 MHz, DMSO-d6) δ (ppm) 23.9, 33.0, 41.2,
119.6, 123.6, 126.9, 133.7, 135.2, 135.4, 145.2, 148.6,
149.0, 158.0, 162.0; HRMS (ESI+) Calcd for C17H20N5O2
[M + H]+: 326.1612; Found 326.1604. Anal. Calcd for
C17H19N5O2: C, 62.75; H, 5.89; N, 21.52. Found: C,
62.23; H, 5.87; N, 21.29.
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N1-(4-Butylphenyl)-N2-(pyridin-3-ylmethyl)diazene-
1,2-dicarboxamide (12)
Yellow solid, yield: 0.266 g (78%), mp 135.5–137.0 °C
(petroleum ether/ethyl acetate); IR: υ 3336, 2953, 2927,
2854, 1728, 1703, 1613, 1540, 1512, 1456 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ (ppm) 0.89 (t, J = 7.5
Hz, 3H), 1.25–1.35 (m, 2H), 1.49–1.60 (m, 2H), 2.56 (t,
J = 7.5 Hz, 2H), 4.52 (d, J = 6.0 Hz, 2H), 7.18–7.27 (m,
2H), 7.38–7.45 (m, 1H), 7.60–7.66 (m, 2H), 7.74–7.80
(m, 1H), 8.48–8.54 (m, 1H), 8.57–8.63 (m, 1H), 9.59 (t,
J = 6.0 Hz, 1H), 11.30 (s, 1H); 13C NMR (126 MHz,
DMSO-d6) δ (ppm) 13.7, 21.7, 33.1, 34.2, 41.1, 119.5,
123.6, 128.8, 133.6, 135.1, 135.4, 139.0, 148.6, 148.9,
157.9, 162.0; HRMS (ESI+) Calcd for C18H22N5O2 [M +
H]+: 340.1766; Found 340.1767. Anal. Calcd for
C18H21N5O2: C, 63.70; H, 6.24; N, 20.64. Found: C,
63.59; H, 6.34; N, 20.59.
N1-(4-(sec-Butyl)phenyl)-N2-(pyridin-3-ylmethyl)dia-
zene-1,2-dicarboxamide (13)
Orange crystals, yield: 0.252 g (74%), mp 163–168 °C
(ethyl acetate); IR: υ 3500, 3277, 2958, 1731, 1702, 1611,
1559, 1514, 1434, 1283 cm–1; 1H NMR (500 MHz, CDC-
l3): δ (ppm) 0.81 (t, J = 7.4 Hz, 3H), 1.22 (d, J = 7.0 Hz,
3H), 1.53–1.62 (m, 2H), 2.57–2.63 (m, 1H), 4.65 (d, J =
6.2 Hz, 2H), 7.19 (d, J = 8.5 Hz, 2H), 7.23–7.28 (m, 1H),
7.59 (d, J = 8.5 Hz, 2H), 7.67–7.71 (m, 1H), 8.07–8.12
(m, 1H), 8.49–8.52 (m, 1H), 8.60 (d, J = 1.8 Hz, 1H), 9.55
(s, 1H); 13C NMR (126 MHz, CDCl3) δ (ppm) 12.2, 21.8,
31.1, 41.1, 42.6, 119.8, 123.8, 127.9, 132.6, 134.2, 136.0,
145.8, 149.1, 149.2, 156.1, 160.2; HRMS (ESI+) Calcd for
C18H22N5O2 [M + H]+: 340.1768; Found 340.1750. Anal.
Calcd for C18H21N5O2: C, 63.70; H, 6.24; N, 20.64.
Found: C, 63.94; H, 6.27; N, 20.21.
N1-(4-Chlorophenyl)-N2-(pyridin-4-ylmethyl)diazene-
1,2-dicarboxamide (14)
Orange solid, yield: 0.211 g (67%), mp 168.8–170.5 °C
(methanol); IR: υ 3675, 3328, 2987, 2901, 1739, 1722,
1609, 1565, 1552, 1510, 1490, 1421, 1402, 1376, 1313,
1279, 1258, 1217 cm–1; 1H NMR (500 MHz, DMSO-d6):
δ (ppm) 4.53 (d, J = 6.1 Hz, 2H), 7.33–7.38 (m, 2H),
7.47–7.53 (m, 2H), 7.74–7.79 (m, 2H), 8.54–8.59 (m,
2H), 9.69 (t, J = 6.10 Hz, 1H), 11.56 (s, 1H); 13C NMR
(126 MHz, DMSO-d6) δ (ppm) 42.4, 121.1, 122.2, 128.7,
129.1, 136.4, 146.9, 149.7, 158.0, 162.0; HRMS (ESI–)
Calcd for C14H11ClN5O2 [M – H]–: 316.0607; Found
316.0620. Anal. Calcd for C14H12ClN5O2: C, 52.92; H,
3.81; N, 22.04. Found: C, 52.91; H, 3.65; N, 22.04.
N1-(4-Methoxyphenyl)-N2-(pyridin-4-ylmethyl)diaze-
ne-1,2-dicarboxamide (15)
Yellow-orange solid, yield: 0.167 g (53%), mp
165.5–167.5 °C (MeOH); IR: υ 3267, 2781, 1701, 1609,
1568, 1550, 1509, 1463, 1439, 1419, 1371, 1323, 1303,
1262, 1246, 1224, 1170, 1022, 1006 cm–1; 1H NMR (500
MHz, DMSO-d6): δ (ppm) 3.76 (s, 3H), 4.53 (d, J = 6.1
Hz, 2H), 6.97–7.02 (m, 2H), 7.33–7.38 (m, 2H),
7.64–7.70 (m, 2H), 8.54–8.59 (m, 2H), 9.62 (t, J = 6.1 Hz,
1H), 11.31 (s, 1H); 13C NMR (126 MHz, DMSO-d6): δ
(ppm) 42.4, 55.3, 114.3, 121.0, 122.2, 130.5, 147.0,
149.7, 156.5, 157.6, 162.3; HRMS (ESI+) Calcd for
C15H16N5O3 [M + H]+: 314.1248; Found 314.1246. Anal.
Calcd for C15H15N5O3: C, 57.50; H, 4.83; N, 22.35.
Found: C, 57.54; H, 4.73; N, 22.28.
N1-(4-Isopropylphenyl)-N2-(pyridin-4-ylmethyl)diaze-
ne-1,2-dicarboxamide (16)
Yellow solid, yield: 0.264 g (81%), mp 162–165 °C (ace-
tone/ethyl acetate); IR υ 3201, 2960, 1708, 1611, 1535,
1261 cm–1; 1H NMR (300 MHz, DMSO-d6): δ (ppm) 1.21
(d, J = 6.9 Hz, 6H), 2.88 (sep, J = 6.9 Hz, 1H), 4.53 (d, J
= 6.0 Hz, 2H), 7.29 (m, 2H), 7.36 (m, 2H), 7.66 (m, 2H),
8.57 (m, 2H), 9.61 (t, J = 6.0 Hz, 1H), 11.27 (s, 1H); 13C
NMR (75 MHz, DMSO-d6): δ (ppm) 23.7, 32.8, 42.3,
119.6, 122.1, 126.8, 135.1, 145.0, 146.8, 149.6, 157.9,
162.1. MS (FAB): m/z 326 (MH+, 73), 107 (62), 71 (93)
55 (100). Anal. Calcd for C17H19N5O2: C, 62.75; H, 5.89;
N, 21.52. Found: C, 62.72; H, 5.91; N, 21.51.
N1-(4-Butylphenyl)-N2-(pyridin-4-ylmethyl)diazene-
1,2-dicarboxamide (17)
Yellow solid, yield: 0.273 g (80.5%), mp 156.0–157.0 °C
(petroleum ether/ethyl acetate); IR: υ 3284, 2923, 2854,
1717, 1608, 1548, 1511, 1420, 1373, 1316 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ (ppm) 0.90 (t, J = 7.5 Hz, 3H),
1.26–1.35 (m, 2H), 1.49–1.60 (m, 2H), 2.57 (t, J = 7.5 Hz,
2H), 4.53 (d, J = 6.0 Hz, 2H), 7.20–7.26 (m, 2H),
7.35–7.40 (m, 2H), 7.61–7.67 (m, 2H), 8.54–8.60 (m,
2H), 9.65 (t, J = 6.0 Hz, 1H), 11.33 (s, 1H); 13C NMR
(126 MHz, DMSO-d6) δ (ppm) 13.7, 21.7, 33.1, 34.2,
42.4, 119.5, 122.2, 128.9, 135.1, 139.1, 147.0, 149.7,
157.9, 162.2; HRMS (ESI+) Calcd for C18H22N5O2 [M +
H]+: 340.1768; Found 340.1769. Anal. Calcd for
C18H21N5O2: C, 63.70; H, 6.24; N, 20.64. Found: C,
63.54; H, 6.24; N, 20.57.
N1-(4-(sec-Butyl)phenyl)-N2-(pyridin-4-ylmethyl)dia-
zene-1,2-dicarboxamide (18)
Yellow solid, yield: 0.258 g (76%); mp 154.6–158.6 °C
(ethyl acetate); IR: υ 3447, 3208, 2961, 2928, 1708, 1611,
1536, 1515, 1260 cm–1; 1H NMR (500 MHz, DMSO-d6):
δ (ppm) 0.77 (t, J = 7.5 Hz, 3H), 1.17 (d, J = 7.0 Hz, 3H),
1.49–1.59 (m, 2H), 2.55–2.62 (m, J = 6.0 Hz, 1H), 4.53
(d, J = 6.0 Hz, 2H), 7.21–7.27 (m, 2H), 7.33–7.39 (m,
2H), 7.60–7.68 (m, 2H), 8.52–8.60 (m, 2H), 9.64 (t, J =
6.0 Hz, 1H), 11.32 (s, 1H); 13C NMR (126 MHz, DMSO-
d6) δ (ppm) 12.1, 21.8, 30.5, 40.4, 42.4, 119.7, 122.2,
127.5, 135.2, 144.0, 147.0, 149.8, 158.0, 162.2. MS
(FAB): m/z 340 (MH+, 100), 107 (34), 93 (54), 69 (31).
Anal. Calcd for C18H21N5O2: C, 63.70; H, 6.24; N, 20.64.
Found: C, 63.65; H, 6.23; N, 20.67.
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N1-(4-(tert-Butyl)phenyl)-N2-(pyridin-4-ylmethyl)dia-
zene-1,2-dicarboxamide (19)
Yellow solid, yield: 0.256 g (75%); mp 180–185 °C (ethyl
acetate/methanol); IR: υ 3198, 3030, 2961, 1707, 1610,
1537, 1516, 1262 cm–1; 1H NMR (300 MHz, DMSO-d6):
δ (ppm) 1.28 (s, 9H), 4.53 (d, J = 5.8 Hz, 2H), 7.35 (m,
2H), 7.43 (m, 2H), 7.65 (m, 2H), 8.56 (m, 2H), 9.60 (t, J =
5.8 Hz, 1H), 11.3 (s, 1H); 13C NMR (75 MHz, DMSO-d6)
δ (ppm) 31.0, 34.1, 42.4, 119.3, 122.1, 125.7, 134.8,
146.9, 147.3, 149.6, 158.0, 162.1. MS (FAB): m/z 340
(MH+, 100), 107 (34), 71 (39), 55 (37). Anal. Calcd for
C18H21N5O2: C, 63.70; H, 6.24; N, 20.64. Found: C,
63.56; H, 6.03; N, 20.79.
5. 2. Biology
5. 2. 1. Cell Culture
Human cervical carcinoma HeLa and laryngeal
carcinoma HEp-2 cells were obtained from cell culture
bank (GIBCO BRL, Invitrogen, Grand Island, USA).
Development of HEp-2 subline resistant to carboplatin
has been published previously.17a These cells are cross-
resistant to anti-cancer drug cisplatin17a and natural
compound curcumin as well.17b Colorectal carcinoma
HCT-116, and lung adenocarcinoma H460 cells were
obtained from American Type Culture Collection
(ATCC; Manassas, VA). All mentioned cell lines were
cultured as a monolayer culture in Dulbecco’s medium
supplemented with 10% fetal serum (Gibco BRL, Invi-
trogen, USA) and cultured in a humidified atmosphere
of 5% CO2 at 37 °C.
5. 2. 2. Compounds
Diazenedicarboxamides were dissolved in DMSO.
They were stored at –20 °C, and diluted to the appropriate
concentrations with growth medium just before use.
5. 2. 3. Cytotoxicity Assay
Cytotoxic activity of new compounds was deter-
mined by MTT assay,18 modified as described. Cells
were seeded into 96-well tissue culture plates (3000
cells/0.18 mL medium/well). The next day different
concentrations of new compounds were added (0.02
mL) to each well and each concentration was tested in
quadruplicate. Following 72 h incubation at 37 °C, the
medium was aspirated, and 20 mg of 3-(4,5-dimethylt-
hiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
dye (Sigma Aldrich, USA) /0.04 mL medium/well was
added. Four hours later, formazan crystals were dissol-
ved in DMSO (0.17 mL/well), the plates were mechani-
cally agitated for 5 min and the optical density at 545
nm was determined on a microtiter plate reader (Aware-
ness Technology Inc, Palm City, FL). Each experiment
was repeated three times.
5. 2. 4. The Role of Glutathione (GSH) in Cell
Response to 10, 11 and 13 
To examine the possible role of GSH in cell respon-
se to the selected diazenedicarboxamides 10, 11 and 13
we used HeLa cells, the model system that we applied for
the screening of new compounds. The cells were seeded
in the morning as described above for the examination of
cytotoxic activity. After 6 h, when the cells were already
attached to the surface of petri dishes, in each well the
specific inhibitor of glutathione synthesis, buthionine sul-
foximine (BSO)12 was added at the final concentration of
0.01 mM. Following the next 18 h, the diazenedicarboxa-
mides 10, 11 or 13 were added at the final concentration
from 2 to 200 mM and 72 h later the cell survival was de-
termined by MTT assay.
5. 2. 5. Type of Cell Death Induced by 10, 11 
and 13
While the cytotoxic assay has shown that diazenes
10, 11 and 13 triggered cell death in all investigated cell
lines, we used again the most sensitive, HeLa cells, to
examine the type of cell death that is triggered by 10, 11
and 13. To determine if the necrosis has occurred, the
loss of membrane integrity was examined, as measured
by massive influx of trypan blue in cells. Cells (3.7 ×
104) were plated in 24 well plates. The next day they we-
re rinsed with a physiological saline, and treated with 34
μM of 10, 100 μM of 11 and 80 μM of 13 for 1 hour. Af-
ter rinsing with saline, the cells were treated with 0.2%
(w / v) trypan blue for 15 minutes. After staining, the
cells were again rinsed with saline, and incubated in sa-
line for further investigation. The cells that have lost the
membrane integrity, i.e. necrotic cells, are clearly stai-
ned blue. Images of stained and unstained cells were ta-
ken at a hundredfold magnification with a Pixera
Pro150ES Camera. 
6. Acknowledgments
This study was supported by the Ministry of
Science, Education and Sport of the Republic of Croa-
tia (Projects 098-0982913-2748; 098-0982913-2850).
Slovenian Research Agency is gratefully acknowledged
for the financial support (project P1-0230; Young Re-
searcher Grant to J.V.). Financial support from Joint
Project BI-HR/12-13-028 is also acknowledged. We
thank Dr. Bogdan Kralj and Dr. Du{an @igon (Mass
Spectrometry Centre, Jo`ef Stefan Institute, Ljubljana,
Slovenia) for recording some of the mass spectra, and
Ms. Ana Rosi} for technical assistance. This work was
supported with the infrastructure of the EN-FIST Cen-
tre of Excellence, Dunajska 156, SI-1000 Ljubljana,
Slovenia.
852 Acta Chim. Slov. 2013, 60, 842–852
Vajs et al.:  Synthesis and Biological Activity of New ...
7. References
1. D. Hanahan, R. A. Weinberg, Cell 2011, 144, 646–674. 
2. (a) S. Rodriguez-Nieto, B. Zhivotovsky, Cur. Pharm. Des.
2006, 12, 4411–4425. (b) A. Ambriovi} Ristov, M. Osmak,
Curr. Sign. Trans. Ther. 2006, 1, 227–237. (c) D. J. Stewart,
Crit. Rev. Oncol. Hematol. 2007, 63, 12–31. (d) B. Köberle,
M. Tomicic, S. Usanova, B. Kaina, Biochim. Biophys. Acta
2010, 1806, 172–182. (e) G. Kelly, A. Strasser, Adv. Cancer
Res. 2011, 111, 39–96. 
3. A. L. Cheng, Y. K. Kang, Z. D. Chen, C. J. Tsao, S. K. Qin, J.
S. Kim, R. C. Luo, J. F. Feng, S. L. Ye, T. S. Yang, J. M. Xu ,
Y. Sun, H. J. Liang, J. W. Liu, J. J. Wang, W. Y. Tak, H. M.
Pan, K. Burock, J. Zou, D. Voliotis, Z. Z. Guan, Lancet
Oncol. 2009, 10, 25–34. 
4. C. Zavaglia, A. Airoldi, A. Mancuso, M. Vangeli, R. Viganò,
G. Cordone, M. Gentiluomo, L. S. Belli, Eur. J. Gastroen-
terol. Hepatol. 2013, 25, 180–186. 
5.J. M. Diamond, J. V. Melo, Leuk. Lymphoma 2011, 52
(Suppl. 1), 12–22.
6. (a) M. Osmak, T. Bordukalo, J. Ko{mrlj, M. Kvajo, Z. Mari-
janovi}, D. Eljuga, S. Polanc, Neoplasma 1999, 46,
201–206. (b) M. Osmak, T. Bordukalo, B. Jernej, J. Ko{mrlj,
S. Polanc, Anti-Cancer Drugs 1999, 10, 853–859. (c) M. Os-
mak, T. Bordukalo, A. Ambriovi} Ristov, B. Jernej, J.
Ko{mrlj, S. Polanc, Neoplasma 2000, 47, 390–395. (d) D.
Moskatelo, S. Polanc, J. Ko{mrlj, L. Vukovi}, M. Osmak,
Pharmacol. Toxicol. 2002, 91, 258–263. (e) D. Moskatelo,
A. Benjak, V. Laketa, S. Polanc, J. Ko{mrlj, M. Osmak, Che-
mother. 2002, 48, 36–41. (f) T. ^imbora, S. Bombek, S. Po-
lanc, M. Osmak, Toxicol. in Vitro 2003, 17, 159–164. (g) S.
Jakopec, K. Dubrav~i}, S. Polanc, J. Ko{mrlj, M. Osmak, To-
xicol. in Vitro 2006, 20, 217–226. (h) S. Jakopec, K. Du-
brav~i}, A. Brozovi}, S. Polanc, M. Osmak, Cell Biol. Toxi-
col. 2006, 22, 61–71. (i) I. Martin-Kleiner, S. Bombek, J.
Ko{mrlj, B. ^upi}, T. ^imbora-Zovko, S. Jakopec, S. Po-
lanc, M. Osmak, J. Gabrilovac, Toxicol. in Vitro 2007, 21,
1453–1459. (j) N. Stojanovi}, D. Urankar, A. Brozovi}, A.
Ambriovi}-Ristov, M. Osmak, J. Ko{mrlj, Acta Chim. Slov.
2013, 60, 368–374.
7. T. Boulikas, M. Vougiouka, Oncol. Rep. 2003, 10, 1663–
1682.
8. (a) A. Meister, Method. Enzym. 1995, 251, 3–7. (b) J. M. , E.
Crit. Rev. Clin. Lab. Sci. 2006, 43, 143–181. 
9. (a) G. Filomeni, G. Rotilio, M. R. Ciriolo, Biochem. Phar-
macol. 2002, 64, 1057–1064. (b) G. I. Giles, Curr. Pharm.
Des. 2006, 12, 4427–4443. (c) M. L. Circu, T. Y. Aw, Free
Radic. Biol. Med. 2010, 48, 749–756.
10. P. Majer, R. S. Randad, J. Org. Chem. 1994, 59, 1937–1938.
11. T. ^imbora-Zovko, S. Bombek, J. Ko{mrlj, L. Kova~i~, S.
Polanc, A. Katalini}, M. Osmak, Drug Dev. Res. 2004, 61,
95–100.
12. O. W. Griffith, A. Meister, J. Biol. Chem. 1979, 254, 7558-
7560.
13. (a) S. Mallakpour, A. R. Hajipour, H. A. Taghizadeh, Mole-
cules 2003, 8, 359–362. (b) J. C. Sticker, W. H. Pirkle, J.
Org. Chem. 1966, 31, 3444–3445.
14. A. Kova~, V. Majce, R. Lenar{i~, S. Bombek, J. M. Bostock,
I. Chopra, S. Polanc, S. Gobec, Bioorg. Med. Chem. Lett.
2007, 17, 2047–2054.
15. R. Lenar{i~, M. Ko~evar, S. Polanc, J. Org. Chem. 1999, 64,
2558–2563. 
16. L. Pieters, J. Ko{mrlj, R. Lenar{i~, M. Ko~evar, S. Polanc,
Arkivoc 2001, Part V, 42–50.
17. (a) M. Osmak, L. Bizjak, B. Jernej, S. Kapitanovi}, Mutat.
Res. 1995, 347, 141–150. (b) S. Rak, T. ^imbora-Zovko, G.
Gajski, K. Dubrav~i}, A. Domijan, I. Dela{, V. Garaj-Vrho-
vac, D. Batini}, J. Sori}, M. Osmak, Toxicol. in Vitro 2013,
27, 523–532.
18. G. Mickisch, S. Fajta, G. Keilhauer, E. Schlick, R. Tschada,
P. Alken, Urol. Res. 1990, 18, 131–136. 
Povzetek
Za ve~jo uspe{nost zdravljenja raka nujno potrebujemo u~inkovitej{a zdravila, kot tudi nove strategije zdravljenja. Na{e
dosedanje raziskave so pokazale, da so {tevilni diazeni citotoksi~ni za razli~ne tumorske celice in da lahko izni~ijo od-
pornost le-teh na cisplatin in vinkristin. Izkazalo se je tudi, da imata nesimetri~na diazendikarboksamida 1 in 2 obeta-
jo~o citotoksi~nost. Cilj sedanje raziskave je bila sinteza novih diazendikarboksamidov, ki bi bili primerno topni in ci-
totoksi~ni. Poro~amo o sintezi in biolo{ki evaluaciji novih N,N’-diazendikarboksamidov. Pokazalo se je, da vodi modi-
fikacija 1 in 2 do aktivnej{ih spojin. Naju~inkovitej{i med vsemi je diazendikarboksamid 11. To spojino lahko obravna-
vamo kot potencialni protitumorski agens za razli~ne tumorje in za nekatere sublinije, ki so odporne na doslej znana
zdravila.
